Relay Therapeutics is trading at $17.77, up 4.53%, with the broader-market rebound the likeliest context for the gain.
- Investors bought beaten-down shares after Thursday’s sell-off, while the October jobs report exceeded expectations.
- No clear company-specific announcement on November 6 explains the gain. The Q3 report, released November 4, reported $848.6 million in cash and runway into 2029.
- The biotech-sector trend was negative, so it does not explain the rise.